Credit: Anna Shvets/Pexels
Theramex has launched a new gel for Vitamin D deficiency, in the hope that it will particularly treat women experiencing pregnancy, menopause, and osteoporosis.
Recent data has suggested that as many as 40% of Europeans are Vitamin D deficient, and this deficiency appears to especially hinder women. In fact, 50% of women hospitalised due to hip fractures derived from osteoporosis were lacking Vitamin D.
Osteoporosis remains largely under-diagnosed and under-treated across Europe, resulting in a large number of fractures. Among people over 50 years old, one in three women will suffer a fragility fracture. Theramex are hoping that easier access to Vitamin D – in the form of their Lundeos gel capsule – will help this problem.
The news follows a recent real-word study from Theramex, showing their Actonel GR drug for osteoporosis has superior efficacy on fracture risk reduction than other similar drugs. The study on 5,000 women showed a 17% lower incidence of fracture, and a 29% reduction in spine fractures.
According to the International Osteoporosis Foundation, there were around 3.5 million people over 50 living with osteoporosis in the UK in 2015. Across Europe, women over 50 are around three times more likely to have the illness than men of the same age.
Robert Stewart, CEO of Theramex, said: “Whether for care through pregnancy, menopause, osteoporosis, or for a healthy lifestyle, many women rely on Vitamin D for their wellbeing.
“In introducing a new Vitamin D to support women, we had three key criteria: It had to be colecalciferol as this is widely regarded as the leading Vitamin D formulation. It should be delivered in a simple, palatable and convenient method. And, there should be flexibility in dosing to suit the needs of women at different phases in their lives.”
He continued: “The launch of Lundeos/Fedivelle, a Vitamin D supplement in the new format of a small soft gel capsule, available in daily or weekly dosages, meets these requirements and will expand the market so that more women are able to access this important therapy.”
Jack Goddard
This is a syndicated feed from Pharmafile
